A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

Fexuprazan is a potassium-competitive acid blocker approved for treating gastric-acid-related diseases. Although the effectiveness of the recent formulation fexuprazan 10 mg has been demonstrated in Phase 3 clinical trials, data on the pharmacokinetics (PKs) of administering fexuprazan 10 mg twice d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Wonsuk, Yang, A-Young, Park, Hyung, Lee, Hyejung, Yoo, Hyounggyoon, Kim, Anhye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458111/
https://www.ncbi.nlm.nih.gov/pubmed/37631056
http://dx.doi.org/10.3390/ph16081141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458111/
https://www.ncbi.nlm.nih.gov/pubmed/37631056
http://dx.doi.org/10.3390/ph16081141

Ejemplares similares